In their article, Vanness and colleagues explore the best way to establish a cost-effectiveness threshold for policy considerations. This may seem an arcane matter in cost-effectiveness analysis that is of interest to few beyond health economists. However, there are several reasons
why this work may profoundly affect everything from clinical guidelines to insurance coverage policies to Medicare negotiation of drug prices.